See more : PFA Invest Balance A (PFIBAA.CO) Income Statement Analysis – Financial Results
Complete financial analysis of Cardio Diagnostics Holdings, Inc. (CDIO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cardio Diagnostics Holdings, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Inox Wind Limited (INOXWIND.NS) Income Statement Analysis – Financial Results
- Moody Technology Holdings Limited (1400.HK) Income Statement Analysis – Financial Results
- Southern Cross Media Group Limited (SXL.AX) Income Statement Analysis – Financial Results
- Li-FT Power Ltd. (LIFFF) Income Statement Analysis – Financial Results
- Hindustan Composites Limited (HINDCOMPOS.NS) Income Statement Analysis – Financial Results
Cardio Diagnostics Holdings, Inc. (CDIO)
About Cardio Diagnostics Holdings, Inc.
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 17.07K | 950.00 | 901.00 | 0.00 |
| Cost of Revenue | 0.00 | 16.00K | 0.00 | 0.00 |
| Gross Profit | 17.07K | -15.05K | 901.00 | 0.00 |
| Gross Profit Ratio | 100.00% | -1,584.21% | 100.00% | 0.00% |
| Research & Development | 145.18K | 40.45K | 31.47K | 1.50K |
| General & Administrative | 6.94M | 4.40M | 470.56K | 591.52K |
| Selling & Marketing | 158.51K | 92.70K | 103.32K | 5.48K |
| SG&A | 7.10M | 4.49M | 573.88K | 597.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 4.00K |
| Operating Expenses | 7.26M | 4.55M | 621.35K | 609.16K |
| Cost & Expenses | 7.26M | 4.55M | 621.35K | 609.16K |
| Interest Income | 1.07K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 6.74M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 111.62K | 16.00K | 16.00K | 10.67K |
| EBITDA | -1.53M | -4.64M | -604.45K | -598.50K |
| EBITDA Ratio | -8,966.90% | -465,254.42% | -67,086.35% | 0.00% |
| Operating Income | -7.24M | -4.55M | -620.45K | -609.16K |
| Operating Income Ratio | -42,440.43% | -478,784.32% | -68,862.15% | 0.00% |
| Total Other Income/Expenses | -1.13M | -112.53K | 0.00 | 4.00K |
| Income Before Tax | -8.38M | -4.66M | -620.45K | -605.16K |
| Income Before Tax Ratio | -49,087.81% | -490,630.00% | -68,862.15% | 0.00% |
| Income Tax Expense | 0.00 | 112.53K | 2.00 | 0.00 |
| Net Income | -8.38M | -4.66M | -620.45K | -605.16K |
| Net Income Ratio | -49,087.81% | -490,630.00% | -68,862.15% | 0.00% |
| EPS | -0.66 | -1.51 | -0.53 | -0.06 |
| EPS Diluted | -0.66 | -1.51 | -0.53 | -0.06 |
| Weighted Avg Shares Out | 12.69M | 3.09M | 1.16M | 9.51M |
| Weighted Avg Shares Out (Dil) | 12.69M | 3.09M | 1.16M | 9.51M |
Cardio Diagnostics Holdings, Inc. Announces Issuance of Second U.S. Patent for Compositions and Methods for Detecting Predisposition to Cardiovascular Disease
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics has announced the issuance of its second U.S. patent.
Cardio Diagnostics Holdings, Inc. Expands HeartRisk™ Platform Offering to Diverse Markets in Conjunction with Nationwide Rollout
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics announced today the nationwide rollout and a significant expansion of its groundbreaking HeartRisk™ platform.
Cardio Diagnostics Holdings, Inc. Expands Partnership with Family Medicine Specialists to Bring Its Specialty Cardiology Tests to Select Walmart Supercenters
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics' AI-driven epigenetic-genetic blood tests will be available Q2 2024 inside the Walmart Supercenter in Round Lake Beach, Illinois.
Houston-Based resTOR Longevity Clinic to Offer Cardio Diagnostics' AI-Driven Epigenetic-Genetic Heart Disease Tests
CHICAGO--(BUSINESS WIRE)--resTOR Longevity Clinic will offer Cardio Diagnostics' blood-based epigenetic-genetic cardiovascular disease tests.
Cardio Diagnostics Holdings, Inc. Accelerates Cardiac Care Innovation with Appointment of Dr. Vimal Ramjee as Strategic Advisor
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics announced the appointment of Dr. Vimal Ramjee, MD FACC CCMS, as a Strategic Advisor.
Cardio Diagnostics Holdings, Inc. Announces the Grant of a Patent in India
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics announced that India's Patent Office has granted a patent to the University of Iowa Research Foundation under patent number 484488.
CORRECTING and REPLACING Cardio Diagnostics Holdings, Inc. Unveils Groundbreaking Employer Cardiovascular Disease Risk Intelligence Platform, HeartRisk™
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics has unveiled HeartRisk, the Company's groundbreaking employer cardiovascular disease risk intelligence platform.
Cardio Diagnostics Holdings, Inc. Unveils Groundbreaking Employer Cardiovascular Disease Risk Intelligence Platform, HeartRisk™
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics has unveiled HeartRisk, the Company's groundbreaking employer cardiovascular disease risk intelligence platform.
American Medical Association (AMA) Grants Cardio Diagnostics a Dedicated CPT PLA Reimbursement Code for Epi+Gen CHD, an AI-powered Test for Assessing the Probability of a Heart Attack or Coronary Heart Disease Event
CHICAGO--(BUSINESS WIRE)--The AMA has granted and assigned Cardio Diagnostics a dedicated CPT® PLA for the company's AI-driven CHD event risk assessment test, Epi+Gen CHD.
American Medical Association (AMA) Grants Cardio Diagnostics Holdings, Inc.'s AI-Powered Coronary Heart Disease Detection Test, PrecisionCHD, a Dedicated CPT PLA Reimbursement Code
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics today announced that the AMA has assigned a dedicated CCPT® PLA) for the company's AI-driven CHD detection test, PrecisionCHD.
Source: https://incomestatements.info
Category: Stock Reports